Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy in first-line metastatic NSCLC
2021-004564-94Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vibostolimab + pembrolizumab, pembrolizumab and vibostolimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-Free Survival. Started Dec 2021; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-004564-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004564-94.